Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)

NCT01675219 is registered in ClinicalTrials.gov with Turku University Hospital as lead sponsor.

NCT NCT01675219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01675219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)
Lead sponsor
Turku University Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2012
Completion date
August 31, 2023
Enrollment
400 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer